(REASON) double-blind, Randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of SagOpilone-induced peripheral Neuropathy

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-000879-26

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Primary Objective: to demonstrate the superiority of ALC over placebo in the prevention of Sagopilone-induced peripheral neuropathy


Critère d'inclusion

  • - Advanced refractory or relapsed ovarian cancer - Patients with metastatic hormone-refractory prostate cancer